BlossomHill Therapeutics, Inc.: Results of Operations and Financial Condition (BLSM)

Nov 12, 2026, 4:47 PM ETResultsRead the original at SEC EDGAR

Good for BLSM

BlossomHill reported FDA agreement on a dose for its lead drug after favorable early data, and it plans a pivotal trial. The trial has not started, and rising costs and a wider loss temper the progress.

BLSM · BlossomHill Therapeutics, Inc.

AI read · Good for BLSM

The AI's read

The FDA's dose agreement follows favorable early safety and efficacy findings. The planned pivotal study gives the lead drug a path toward testing in more patients. BlossomHill also had $224.9 million in cash. Spending rose, and its quarterly loss widened to $24.0 million from $16.0 million. The drug is still being tested, but progress and cash outweigh the higher costs in this report.

Get alerts for BLSM

Follow BlossomHill Therapeutics, Inc. (BLSM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BLSM

Free on the App Store and Google Play, or on the web.